NO20003529L - Treatment of dyskinesia conditions - Google Patents

Treatment of dyskinesia conditions

Info

Publication number
NO20003529L
NO20003529L NO20003529A NO20003529A NO20003529L NO 20003529 L NO20003529 L NO 20003529L NO 20003529 A NO20003529 A NO 20003529A NO 20003529 A NO20003529 A NO 20003529A NO 20003529 L NO20003529 L NO 20003529L
Authority
NO
Norway
Prior art keywords
dyskinesia
treatment
conditions
levodopa
individual
Prior art date
Application number
NO20003529A
Other languages
Norwegian (no)
Other versions
NO20003529D0 (en
Inventor
Eldad Melamed
Ruth Djaldetti
Ilan Ziv
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12288398A external-priority patent/IL122883A0/en
Priority claimed from IL12710298A external-priority patent/IL127102A0/en
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Publication of NO20003529D0 publication Critical patent/NO20003529D0/en
Publication of NO20003529L publication Critical patent/NO20003529L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Levodopa-indusert dyskinesi og tardiv dyskinesi forbedres ved administrering av riluzol til et individ som har behov for dette.Levodopa-induced dyskinesia and tardive dyskinesia are improved by administering riluzole to an individual in need.

NO20003529A 1998-01-09 2000-07-07 Treatment of dyskinesia conditions NO20003529L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12288398A IL122883A0 (en) 1998-01-09 1998-01-09 Pharmaceutical compositions for the treatment of dyskinesias
IL12710298A IL127102A0 (en) 1998-11-17 1998-11-17 Pharmaceutical compositions for the treatment of dyskinesias
PCT/IL1999/000003 WO1999034785A2 (en) 1998-01-09 1999-01-05 Treatment of dyskinesias

Publications (2)

Publication Number Publication Date
NO20003529D0 NO20003529D0 (en) 2000-07-07
NO20003529L true NO20003529L (en) 2000-09-08

Family

ID=26323572

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003529A NO20003529L (en) 1998-01-09 2000-07-07 Treatment of dyskinesia conditions

Country Status (10)

Country Link
EP (1) EP1043996A2 (en)
JP (1) JP2002500181A (en)
KR (1) KR20010033978A (en)
CN (1) CN1290166A (en)
AU (1) AU1780699A (en)
BR (1) BR9906821A (en)
CA (1) CA2317811A1 (en)
NO (1) NO20003529L (en)
PL (1) PL342098A1 (en)
WO (1) WO1999034785A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054772A1 (en) * 1999-03-12 2000-09-21 Aventis Pharma S.A. Amyotropic lateral sclerosis treatment with a combination of riluzole and an ampa receptor antagonist
FR2790670A1 (en) * 1999-03-12 2000-09-15 Aventis Pharma Sa Treatment or prevention of amyotrophic lateral sclerosis, using synergistic combination of riluzole and AMPA receptor antagonist, e.g. 5H,10H-imidazo (1,2-a) indeno (1,2-e) pyrazin-4-one derivative
FR2801793B1 (en) * 1999-12-01 2003-07-04 Aventis Pharma Sa COMBINATION OF ERGOLIN AND RILUZOLE AND ITS USE AS A MEDICINAL PRODUCT
US6297254B1 (en) 1999-12-01 2001-10-02 Aventis Pharma S. A. Method for the prevention or treatment of a motoneuron disease
FR2809620B1 (en) * 2000-06-05 2002-08-02 Aventis Pharma Sa USE OF RILUZOLE OR ITS SALTS FOR THE PREVENTION AND TREATMENT OF ADRENOLEUCODYSTROPHY
PT1256340E (en) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh TRANSERMMED THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (en) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa APPLICATION OF AMINO-2 TRIFLUOROMETHOXY-6 BENZOTHIAZOLE TO OBTAIN A MEDICINE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.
FR2700117B1 (en) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application of anti-convulsants in the treatment of Parkinson's disease and parkinsonian syndromes.

Also Published As

Publication number Publication date
NO20003529D0 (en) 2000-07-07
EP1043996A2 (en) 2000-10-18
CA2317811A1 (en) 1999-07-15
JP2002500181A (en) 2002-01-08
PL342098A1 (en) 2001-05-21
WO1999034785A3 (en) 1999-09-16
CN1290166A (en) 2001-04-04
AU1780699A (en) 1999-07-26
KR20010033978A (en) 2001-04-25
BR9906821A (en) 2000-10-17
WO1999034785A2 (en) 1999-07-15

Similar Documents

Publication Publication Date Title
NO20062508L (en) Administration of levodopa and carbidopa
ATE413386T1 (en) PPAR-GAMMA MODULATORS
DK0858330T3 (en) Compositions containing derivatives of hydroperoxyeicosatetraenoic acid and methods of use in the treatment of disease
NO20014986L (en) 4,5-Diaryl-3 (2H) -furanone derivatives as cyclooxygenase-2 inhibitors
DK1169060T3 (en) Sodium channel blocker preparations and their use
FR16C0028I2 (en) VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODS
ATE344029T1 (en) TREATING TYPE II DIABETES WITH DIPEPTIDYL PEPTIDASE IV INHIBITORS
DE60229971D1 (en) PREPARATIONS FOR IRRITATIVE ROSACEA TREATMENT
DK1651161T3 (en) Pharmaceutical compositions and methods for promoting wound healing
DE69630955D1 (en) IMMORTALIZATION OR DISIMMORTALIZATION OF CELLS
DK0817637T3 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC or FTC
DK1097173T3 (en) Use of IL-2 peptides and derivatives thereof as therapeutic agents
DK1401869T3 (en) Molecules and Methods for Inhibiting Germ Excretion 1
DK0696456T3 (en) Combination of necrosis agents with necrosis-activated substances for selective treatment of tumors and inflammatory diseases
DE602004017871D1 (en) PREPARATIONS FOR THE TREATMENT OF ARTHRITICAL APPEARANCE
NO982874L (en) Pharmaceutical preparations with vitamin D analogues
NO20062978L (en) Reduction of dermal scarring
AU2001258373A1 (en) Method for identifying helicobacter antigens
ATE309811T1 (en) ANALGESIC FROM SNAKE VENOM
DK1517694T3 (en) plant Extracts
AR009819A1 (en) PROTEASE INHIBITORS STABILIZED PROTEINS AND THEIR VARIABLES
DK1183037T3 (en) Compositions for modulating immune response and for treating inflammatory diseases
BR0316488A (en) Methods for modulating lacunar junction communication in a cell population, and for treating a patient having or at risk of developing a pathological condition involving poor lacunar junction communication, use of a peptide, and pharmaceutical composition
EA200401032A1 (en) ANTIINFARCT MOLECULES
DK1143917T3 (en) Anti-convulsive derivatives suitable for the treatment of post-traumatic stress disorder

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application